





ype 2 diabetes mellitus (DM2) is the most com-
mon endocrine disease and is one of the most 
acute medical and social problems because it leads 
to early disability and an increase in mortality among the 
population due to the development of various complica-
tions [1]. Currently, more than 415 million people aged be-
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Одной из наиболее продуктивных современных технологий геномных исследований сахарного диабета 2 типа (СД2) 
является анализ ассоциаций полиморфных маркеров генов-кандидатов с развитием заболевания.
Цель. Изучение ассоциации полиморфных генетических маркеров факторов некроза опухоли и их рецепторов 
(rs1800629 TNFα, rs909253 Ltα, rs767455 TNFR1, rs1061624 TNFR2) с формированием СД2 среди населения Цен-
трального Черноземья РФ.
Материалы и методы. Проведен анализ результатов наблюдений 544 человек из русских жителей Центрального 
Черноземья России: 236 пациентов с установленным диагнозом СД2 (диагноз установлен на основании стандартных 
диагностических критериев) и 308 человек контрольной группы. Анализ всех локусов осуществлялся методом ПЦР 
синтеза ДНК, с использованием TaqMan зондов. Статистический анализ распределения частот генотипов прово-
дили с использованием таблиц сопряженности и критерия χ2, р≤0,05. 
Результаты. Анализ методом «случай-контроль» показал, что генотип GG rs909253Ltα является фактором риска 
развития СД2 (OR=2,36, р=0,01). Установлено, что индивидуумы с генотипом AA rs767455 TNFR1 отличаются ран-
ним возрастом манифестации СД2 по сравнению с больными, имеющими генетические варианты AG и GG (р=0,01). 
Заключение. В результате проведенного исследования впервые продемонстрирована вовлеченность полиморфных 
маркеров генов факторов некроза опухоли и их рецепторов в формирование СД2 у русских жителей Центрального 
Черноземья России.
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Study of the associations between polymorphic markers rs1800629 TNFα, rs909253 Ltα, rs767455 
TNFR1, rs1061624 TNFR2 and the development of type 2 diabetes
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Aim. To study the association between polymorphic genetic markers, tumor necrosis factors and their receptors (rs 1800629 
TNFα, rs 909253 Ltα, rs 767455 TNFR1, rs 1061624 TNFR2) and the development of type 2 diabetes (T2D) among the 
population of the Central Black Earth Region of Russia.
Materials and methods. The results obtained from 544 patients, of which 236 were already diagnosed with T2D and 308 were 
healthy control individuals, were analysed. All the loci were analysed by DNA synthesis using PCR TaqMan probes. The sta-
tistical analysis of the frequency distribution of genotypes was performed using contingency tables and the χ2 test, with p ≤ 0.05.
Results. A case-control analysis showed that genotype GG rs 909253Ltα was a risk factor for T2D (OR = 2.36, p = 0.01). Also, 
individuals with genotype AA rs 767455TNFR1 had significantly earlier age of T2D manifestation than that of patients with 
genetic variants AG and GG (p = 0.01).
Conclusion. This study demonstrated the involvement of polymorphic markers of tumor necrosis factors and their receptors in 
the development of T2D among the residents of the Central Black Earth Region of Russia.
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tween 20 and 79 years worldwide suffer from DM, and 90% 
of these cases are DM2. Correspondingly, in Russia, more 
than 4 million people have DM, of which 3.7 million have 
DM2 [2]. In terms of the incidence of disability and mortal-
ity, DM ranks third after cardiovascular diseases and cancer. 
Meanwhile, epidemiological studies conducted by the Fed-
eral State Budgetary Institution Endocrinology Research 
Center of the Ministry of Health of the Russian Federation 
from 2002 to 2010 showed that the true number of patients 
with DM in Russia is approximately 3–4 times greater than 
that officially registered and reaches 9–10 million people, 
which is approximately 7% of the population [3].
DM2 is often referred to as a multifactorial disease. Ac-
cording to the literature, the role of genetic factors in the 
development of DM2 amounts for 15%–50% [4]. Recent 
research has shown that cytokines that contribute to the de-
velopment of insulin resistance play an important role in the 
development of DM2, with tumour necrosis factors (TNFs) 
being one of the key mediators of its development [5]. TNFs 
[TNFα and lymphotoxin-α (Ltα)] have a wide range of bi-
ological effects (such as immunomodulatory, cytotoxic and 
proinflammatory effects; stimulation of lipolysis; activation 
of the haemostasis system and induction of apoptosis) which 
may influence the development and progression of DM2 [6].
It is known that hyperproduction of TNFα leads to 
a decrease in the sensitivity to the action of insulin and 
consequently, a change in the metabolism of glucose in the 
adipose and muscle tissues and the liver. It has also been es-
tablished that in the presence of obesity and insulin resist-
ance, TNFα is synthesised in large quantities in the adipose 
and muscle tissue and exhibits both para- and autocrine 
properties [7]. Ltα is a chemoattractant for neutrophils, 
stimulates the formation of peroxide ions, enhances phago-
cytosis and adhesion to the endothelium, stimulates fibro-
blast activity, induces the production of stress hormones 
and affects glucose metabolism [8]. TNFs (TNFα and 
Ltα) implement their biological effects through specific 
type 1 and 2 receptors (TNFR1 and TNFR2, respectively). 
TNFR1 is responsible for acute inflammatory responses 
and is expressed by most cell types. TNFR2 is mainly in-
volved in the implementation of metabolic effects of TNFs, 
namely, regulating adipose tissue and carbohydrate metab-
olism. Thus, TNFs can influence the development and pro-
gression of DM2 through their receptors.
From the molecular and genetic points of view, DM2 
is studied quite actively both abroad and in the Russian 
Federation [9]. However, results of studies investigating the 
relationship of candidate genes of TNFs and their receptors 
with the development of DM2 are ambiguous in different 
populations. For example, it was demonstrated that allele 
A rs1800629 TNFα is a risk factor for DM2 development in 
Iranian [odds ratio (OR) = 2.34] [10], Indian (OR = 3.21) 
[11] and Brazilian (OR = 1.82) [12] populations. However, 
among the populations of Croatia and Hungary, this as-
sociation could not be confirmed [13]. In contrast, in the 
Mexican population, it was found that the risk factor for 
DM2 development is the genotype GG rs1800629 TNFα 
(OR = 3.64) [14].
The role of polymorphic genetic markers of TNFs and 
their receptors in DM2 in our country has not been suffi-
ciently studied, which necessitates conducting these stud-
ies in various populations of the Russian Federation.
AIM
The aim of this study was to investigate the associa-
tion of polymorphic markers of TNFs and their receptors 
(rs1800629 TNFα, rs909253 Ltα, rs767455 TNFR1, and 
rs1061624 TNFR2) with the development of DM2 among 
the population of the Central Black Soil Region of the Rus-
sian Federation.
MATERIALS AND METHODS
The results of observations of 544 people were 
analysed: 236 patients with an established diagnosis of 
DM2 and 308 patients in the control group. Patients 
with DM2 and those in the control group included 
individuals of Russian nationality who were natives of 
the Central Black Soil Region of Russia and were not 
related. Diagnosis of DM2 was established after a detailed 
clinical and laboratory examination of patients in the 
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Demographic and clinical characteristics of the study groups
Index Patients (N = 236) Control (N = 308) p
Gender (m/f) 64/172 82/226 >0.05
Age, years 57.85±6.11 60.20±6.28 >0.05
Age of onset, years 48.2±0.48 - -
Duration of diabetes, years 9.7±0.37 - -
Body mass index, kg/m2 29.7±4.8 27.3±5.5 >0.05
Glycated haemoglobin, % 8.77± 0.13 - -
Fasting plasma glucose, mmol/l 9.6±1.7 5.6±1.1 <0.05
Plasma glucose level 2 h after a meal, mmol/l - 6.8±0.8 -
Basal insulin level, μU/ml 14.8±9.1 10.2±4.9 <0.05
Insulin level 2 h after a meal, μU/l - 46.5±21.7 -
Specific weight of patients with hereditary burden on DM2, n, % 103 
Table 1






Department of Endocrinology of the Belgorod regional 
clinical hospital of St. Joasaph based on the criteria of the 
WHO Expert Committee (1999) and the Fede’ral Target 
Program ‘Diabetes Mellitus’ (2002). The control group 
included age- and sex-matched individuals without DM2. 
All patients signed the informed consent form prior to 
inclusion in the study.
The groups studied were comparable in terms of their 
basic biological parameters including gender, age and body 
mass index (Table 1).
Venous blood (8–9 ml) taken from the basilic vein of 
the proband was used for molecular and genetic studies. 
Isolation of genomic DNA from the peripheral blood was 
performed by phenol-chloroform extraction using a stand-
ard protocol.
Analysis of all loci (rs1800629 TNFα, rs909253 Ltα, 
rs767455 TNFR1, and rs1061624 TNFR2) was performed 
by polymerase chain reaction (PCR) on isolated DNA. 
PCR was performed on an IQ5 thermocycler (Bio-Rad, 
Hercules, CA, USA), with Thermus aquaticus DNA pol-
ymerase (Silex-M, Moscow, Russia) and oligonucleotide 
primers and probes synthesised by Sintol (Moscow, Russia) 
(Table 2). Genotyping was performed by the method of dis-
crimination of alleles using TaqMan probes. Designations 
of polymorphic markers are given in accordance with the 
dbSNP database.
Construction of the database and statistical calculations 
were performed using the program STATISTICA 6.0. 
Determination of phenotypic and gene frequencies was 
conducted by standard methods. To assess the compliance 
of the observed distribution to the expected one, the 
χ2 criterion was used based on the Hardy–Weinberg 
equilibrium.
Statistical analysis of the distribution of the frequency 
of genotypes was performed using contingency tables and 
the Yates corrected chi-square test (χ2) for continuity and 
OR with 95% confidence interval. In a comparative analysis 
of qualitative indicators characterising patients with DM2 
and those in the control group, the nonparametric Mann–
Whitney test was used [15]. 
Ethics statement
The study protocol was approved by the ethics 
committee of Belgorod State University (Belousova O.N., 
Department of Medical and Biological Disciplines), 
protocol No. 3, 14/05/2009.
RESULTS AND DISCUSSION
Investigation of the genotype frequencies of genetic mark-
ers studied showed that for all the loci examined in patients 
in the control group and in patients with DM2, the empirical 
distribution of the genotypes corresponds to the theoretically 
expected distribution by Hardy–Weinberg equilibrium (p > 
0.05). Similarly, the observed heterozygosity (H0) did not dif-
fer from the expected heterozygosity (HE) (p > 0.05).
The case-control analysis (patients with DM2–healthy 
individuals) revealed the presence of a statistically significant 
association of the polymorphic marker rs909253 Ltα with the 
development of DM2. The GG genotype significantly increased 
the risk of DM2 development (OR = 2.36, p = 0.01) (Table 3).
Note: H0 and HE are the observed and expected 
heterozygosity, respectively.
Data obtained in the current study correspond to 
the literature on the biological significance of Ltα in the 
body. Ltα has pronounced proinflammatory, cytotoxic and 
immunomodulatory actions, and these mechanisms play 
important roles in the etiopathogenesis of DM2 [16]. It 
should be emphasised that the genotype GG rs909253 Ltα 
controls the increased production of Ltα. Therefore, in 
individuals with this genotype, we can also expect more 
pronounced etiopathogenetic effects of Ltα [17]. Notably, 
to the best of our knowledge, this is the first study to 
establish the importance of the locus rs909253 of Ltα in 
DM2 among the Russian population.
No significant differences in the frequencies of 
alleles and genotypes were revealed in the other genetic 
polymorphisms investigated (p > 0.05).
When analysing the age of DM2 onset, it was established 
that individuals with genotype AA rs767455 TNFR1 have an 
earlier age of DM2 onset (x ± SD = 47.01 ± 0.92 years) 
Conditions of amplification, sequences of primers and fluorescent probes





















FAM: CACAACCCGCTGCC - RTQ1
ROX: CCACAACTCGCTGCC - BHQ2
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compared with patients with the genetic variants AG and 
GG rs767455 TNFR1 (x ± SD = 48.99 ± 0.72 years, p = 
0.01) (Table 4).
Data obtained indicate a significant effect of rs767455 
TNFR1 on the age of DM2 onset. According to the literature 
[18], TNFR1 mediates the functions of multiple types of ac-
tion of TNFs, thereby participating in the implementation of 
a wide range of biological processes in the body (mitogenesis 
in adipocyte, apoptosis, stimulation of leptin secretion, reg-
ulation of mitochondrial functions, participation in the regu-
lation of the metabolism of carbohydrates and fats, induction 
of insulin resistance in the adipose tissue and muscles and 
suppression of insulin secretion by β-cells of pancreatic is-
lets) that are important in the etiopathogenesis of DM2 
[19]. According to the literature, the genotype AA rs767455 
TNFR1 is associated with an increase in the expression of the 
receptor of TNF 1pe [20], which may cause an early age of 
DM2 onset.
CONCLUSION
The importance of polymorphic markers of Ltα 
(rs909253 Ltα) and TNFR1 (rs767455 TNFR1) in the 
development of DM2 in Russian residents of the Central 
Black Earth Region should be noted. The genotype GG 
rs909253 Ltα is a risk factor for the development of DM2 
(OR = 2.36), whereas individuals with the genotype AA 
rs767455 TNFR1 have an earlier age of DM2onset than 
Distribution of polymorphic markers of genes of tumour necrosis factors and their receptors in patients with DM2 and in those in the control 
group
Loci Alleles, genotypes
Patients with DM2  
(N = 236)
Control group
(N = 308) ОR (95% СI) χ2; p
 (%)  (%)
rs909253 Ltα
A 341 (72.25) 473 (77.04) 0.77  (0.58-1.03) χ2=3.01;  p=0.08
G 131 (27.75) 141 (22.96) 1.29  (0.97-1.74) χ2=3.01;  p=0.08
AA 129 (54.66) 180 (58.63) 0.85 (0.59-1.81) χ2=0.70;  p=0.40
AG 83 (35.16) 113 (36.80) 0.93 (0.64-1.34) χ2=0.09;  p=0.76
GG 24 (10.18) 14 (4.57) 2.36  (1.14-4.95) χ2=5.61;  p=0.01
H0(HE).  PHWE 0.35 (0.40).  >0.05 0.36 (0.35).  >0.05
rs1800629 TNFα
G 405 (85.81) 539 (88.94) 0.75  (0.91-1.94) χ2=2.12;  p=0.14
A 67 (14.19) 67 (11.06) 1.33 (0.51-1.09) χ2=2.12;  p=0.14
GG 176 (74.57) 242 (79.87) 0.73  (0.48-1.13) χ2=1.84;  p=0.17
AG 53 (22.45) 55 (18.15) 1.30 (0.83-2.05) χ2=1.27;  p=0.25
AA 7 (2.98) 6 (1.98) 1.51  (0.45-5.15) χ2=0.20;  p=0.64
H0(HE).  PHWE 0.22 (0.24). >0.05 0.18 (0.19).>0.05
rs767455 TNFR1
G 237 (50.42) 318 (51.62) 0.94 (0.73-1.21) χ2=0.16;  p=0.68
A 235 (49.58) 298 (48.38) 1.05 (0.82-1.35) χ2=0.16;  p=0.68
GG 66 (27.96) 76 (24.68) 1.18 (0.79-1.77) χ2=0.58;  p=0.44
AG 106 (44.91) 166 (53.89) 0.69 (0.48-0.99) χ2=3.95;  p=0.04
AA 64 (27.13) 66 (21.43) 1.36 (0.90-2.06) χ2=2.07;  p=0.15
H0(HE).  PHWE 0.44 (0.50) >0.05 0.53 (0.49) >0.05
rs1061624 TNFR2
G 272 (57.63) 341 (55.74) 1.07 (0.83-1.37) χ2=0.25;  p=0.61
A 200 (42.37) 269 (44.26) 0.93  (0.72-1.19) χ2=0.25;  p=0.61
GG 81 (34.32) 101 (33.12) 1.05 (0.72-1.53) χ2=0.04;  p=0.83
AG 110 (46.61) 138 (45.24) 1.05  (0.74-1.50) χ2=0.05;  p=0.81
AA 45 (19.07) 66 (21.64) 0.85  (0.54-1.33) χ2=0.39;  p=0.53
H0(HE).  PHWE 0.46(0.48) >0.05 0.43(0.49). >0.05
Table 3
Note: H0 and HE are the observed and expected heterozygosity, respectively
Demographic and clinical characteristics of patients with DM2, depending on the genotypes of the locus rs767455 TNFR1
Indices
Genotype on locus rs767455 TNFR1
р
АА (n=64) АG и GG(n=175)
Age, years 56.93±0.79 58.53±0.76 0.06
Age of onset, years 47.01±0.92 48.99±0.72 0.01
Duration of diabetes, years 9.92±0.67 9.60±0.59 0.06
Body mass index, kg/m2 31.71±0.68 33.19±0.49 0.06
Glycated haemoglobin, % 9.12±0.25 8.65±0.22 0.06
Table 4
Note: x is the mean, SD is the standard quadratic deviation






patients with the genetic variants AG and GG rs767455 
TNFR1 (p = 0.01). To the best of our knowledge, this is the 
first time this has been demonstrated in this population.
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